ADARx Pharmaceuticals aims to raise $371.9 million in US IPO - TradingView
Why now
Thesis: Biotech IPO size disclosed, issuer not on allowed slug list, sector-sentiment only.
Catalyst to watch: IPO pricing and demand.
Main risk: Weak biotech IPO market sentiment.
Why it matters
Biotech IPO size disclosed; issuer not on allowed slug list, so impact is sector-sentiment only.
Related assets & topics
HealthcareSources
- googlenews · news.google.com · 2026-09-21 10:13 UTC